ClickHouse Announces Strategic Collaboration Agreement with AWS to Advance Real-Time Data Analytics and Generative AI Innovation
10.12.2024 15:00:00 CET | Business Wire | Press release
ClickHouse, Inc., a leader in real-time analytics, announced today that it has signed a five-year strategic collaboration agreement (SCA) with Amazon Web Services (AWS), designed to accelerate innovation in real-time data warehousing, observability, business intelligence, machine learning, and generative AI solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210976702/en/
ClickHouse announces strategic collaboration agreement with AWS (Graphic: Business Wire)
The partnership will expand on ClickHouse’s relationship with AWS and introduce new integrations between ClickHouse Cloud and AWS services including Amazon Data Firehose, Amazon Relational Database Service (RDS), AWS Glue, and Amazon Bedrock. Together, this will make it easier for customers to build and manage high-performance analytics and generative AI applications. Additionally, this will provide customers with seamless deployment, enhanced interoperability, and optimal performance of data-intensive workloads powered by ClickHouse on AWS.
In addition to tighter integrations, ClickHouse and AWS will create new tailored industry solutions for customers ranging from finance to e-commerce to gaming. These solutions will enable organizations to harness the power of ClickHouse’s real-time analytics engine alongside AWS services to drive transformational outcomes. The two companies will also work on joint go-to-market activities to empower enterprises with advanced tools to extract actionable insights from their data at scale.
“The reliable infrastructure and global reach of AWS were crucial for the successful launch of ClickHouse Cloud,” said Aaron Katz, CEO of ClickHouse. “Our AWS Marketplace listing significantly expanded our customer reach, while the AWS Partner Network helped us engage with enterprise clients. This led to 150% incremental growth in our customer base on AWS Marketplace in 2024. Now with the strategic collaboration agreement, we strengthen focus on integrations, joint solutions and go-to-market activities to help customers unlock the full potential of their data and drive innovation in their respective industries.”
“We continue to invest in helping growth-stage companies, like ClickHouse, leverage AWS infrastructure, resources, and services like AWS Marketplace to rapidly grow and scale their businesses,” said Julia Chen, Vice President AWS Partner Core. “By integrating ClickHouse Cloud with AWS services such as Amazon Bedrock, customers can leverage the strength of both companies to more easily build advanced real-time applications, such as instant fraud detection, adaptive user experiences, and dynamic operational intelligence—unlocking new possibilities to stay ahead in today’s competitive landscape.”
Helping customers get the best business value from their data lake and data analytics investments is central to the collaboration between ClickHouse and AWS. Since launching ClickHouse Cloud on AWS in 2022, thousands of ClickHouse deployments have already been created, supporting joint customers ranging from startups to Fortune 500 companies. Every day, ClickHouse customers on AWS run over 2 billion queries scanning over 1.5 quadrillion records on top of 50 petabytes of data.
"By migrating our analytics workloads to ClickHouse Cloud on AWS we simplified the integration with data residing in AWS, achieved significant improvement in query performance, and project much lower annual costs. This has let us build new features faster that help our customers better understand their consumers and how their engagement strategies are performing," said Jon Hyman, Cofounder and Chief Technology Officer at Braze [NASDAQ: BRZE].
This collaboration underscores the value of ClickHouse and AWS to provide flexibility and unlock greater business value for customers across industries. For more information please visit: www.clickhouse.com
About ClickHouse
ClickHouse is a fast, open-source columnar database management system that allows for real-time data processing and analytics. Engineered for high performance, ClickHouse Cloud delivers exceptional query speed, making it an ideal solution for handling large volumes of data. Trusted by leading companies like Lyft, Deutsche Bank, and LangChain, ClickHouse Cloud enables businesses to gain critical insights and drive decision-making with its scalable, efficient, and robust data infrastructure. For more information, visit clickhouse.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210976702/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom